Ivermectin to Control Malaria – A Cluster-Randomized Trial (2025)

Peer-Reviewed Study · Chaccour C, Maia M, Kariuki M, Ruiz-Castillo P, Wanjiku C, Kasiwa L, Brazeal A, Casellas A, et al. (BOHEMIA trial investigators) · July 24, 2025

Chaccour C et al., 2025-07-24: The Kenya arm of BOHEMIA: monthly mass ivermectin at 400 micrograms/kg for three months in 84 clusters lowered malaria infection incidence in children aged 5-15 by 26% compared with albendazole, with no safety signal.

the adjusted incidence rate ratio (ivermectin vs. albendazole) was 0.74 (95% confidence interval [CI], 0.58 to 0.95, P = 0.02).

Chaccour C et al., 2025-07-24: The Kenya arm of BOHEMIA: monthly mass ivermectin at 400 micrograms/kg for three months in 84 clusters lowered malaria infection incidence in children aged 5-15 by 26% compared with albendazole, with no safety signal. Trial name: BOHEMIA (Broad One Health Endectocide-based Malaria Intervention in Africa), Kenya arm. Cluster-randomized trial, 84 clusters, 28,932 eligible participants, Kwale County, coastal Kenya, high bed-net coverage; ivermectin 400 micrograms/kg orally once a month for 3 consecutive months at the start of the short rains; comparator albendazole 400 mg (active control). Primary outcomes: cumulative malaria infection incidence in children 5-15 (2.20 vs 2.66 per child-year; IRR 0.74, 0.58-0.95, P=0.02) and adverse events (serious AE IRR 0.63, 0.21-1.91). Funded by Unitaid; NCT04966702; PACTR202106695877303. No conflicts declared in the PubMed record. Published 2025-07-24 issue date; the trial paper title as indexed is 'Ivermectin to Control Malaria – A Cluster-Randomized Trial'. Study type: randomized trial.